Verona Pharma plc Stock News

Verona Pharma plc (NASDAQ:VRNA ) Q3 2022 Earnings Conference Call November 9, 2022 9:00 AM ET Company Participants David Zaccardelli – Chief Executive Officer Mark Hahn – Chief Financial Officer K

LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the follow

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile pric

LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato

Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrin

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overvie

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. BBQ Holdings, Inc. (NAS

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday. The Dow traded down 0.34% to 32,720.07 while the NASDAQ fell 1.38% to 12,470.08. The S&

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for CO

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday. The Dow traded down 0.12% to 32,794.11 while the NASDAQ fell 1.54% to 12,450.29. The S&P also fell, dr

Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The company reported overwhelmingly positive results from a late-stage study of its COPD drug candidate.

Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The c

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.06% to 32,853.24 while the NASDAQ fell 0.75% to 1

Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).